Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 11/20 | 0.67 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.62 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.60 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.60 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.60 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.60 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.60 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.60 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.60 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.58 |
| ▸ | NAMPT | P43490 | 3/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | LIPE | Q05469 | 1/20 | 0.55 |
| ▸ | KIT | P10721 | 1/20 | 0.55 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13873393 | 0.84 | CYP2C9 (0.76) | EPHX2HSD11B1CYP2C9CYP2C19LIPE | |
| SCHEMBL1147132 | 0.83 | EPHX2 (0.58) | EPHX2HSD11B1LIPEHRH3 | |
| SCHEMBL15170994 | 0.83 | EPHX2 (0.76) | EPHX2 | |
| SCHEMBL4558228 | 0.82 | EPHX2 (0.91) | EPHX2NAMPTCYP2C9CYP2C19 | |
| SCHEMBL15387520 | 0.81 | EPHX2 (0.56) | EPHX2HSD11B1NAMPTLIPE | |
| SCHEMBL12893826 | 0.81 | EPHX2 (0.59) | EPHX2PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL7972857 | 0.81 | HSD11B1 (0.62) | EPHX2HSD11B1S1PR2LIPEHRH3 | |
| SCHEMBL3940878 | 0.81 | EPHX2 (1.00) | EPHX2HRH3 | |
| SCHEMBL10253415 | 0.81 | CNR2 (0.80) | EPHX2PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL13873283 | 0.80 | EPHX2 (1.00) | EPHX2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040092528-A1 | Agent for modulating excitatory synaptic transmission comprising a compound having alpha7 nicotinic acetylcholine receptor activation property | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-05-13 | — | — | US | disclosed |
| US-6710043-B1 | POSSESS THE POTENTIATION OF THE CHOLINERGIC ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-03-23 | — | — | US | disclosed |
| US-20040014745-A1 | Amide compounds | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2004-01-22 | — | — | US | disclosed |
| EP-1315494-A1 | AGENT FOR MODULATING EXCITATORY SYNAPTIC TRANSMISSION COMPRISING A COMPOUND HAVING ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATION PROPERTY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-06-04 | — | — | EP | disclosed |
| EP-1235575-A2 | AGENT FOR EXPRESSION OF LONG-TERM POTENTIATION OF SYNAPTIC TRANSMISSION COMPRISING COMPOUND HAVING BRAIN SOMATOSTATIN ACTIVATION PROPERTY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-09-04 | — | — | EP | disclosed |
| WO-2002020016-A1 | AGENT FOR MODULATING EXCITATORY SYNAPTIC TRANSMISSION COMPRISING A COMPOUND HAVING ALPHA α7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATION PROPERTY | FUJISAWA PHARMACEUTICAL CO, LTD (JP) | 2002-03-14 | — | — | WO | disclosed |
| WO-2000072834-A9 | AGENT FOR EXPRESSION OF LONG-TERM POTENTIATION OF SYNAPTIC TRANSMISSION COMPRISING COMPOUND HAVING BRAIN SOMATOSTATIN ACTIVATION PROPERTY | FUJISAWA PHARMACEUTICAL CO (JP) | 2001-12-20 | — | — | WO | disclosed |
| EP-1140836-A1 | AMIDE COMPOUNDS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000072834-A2 | AGENT FOR EXPRESSION OF LONG-TERM POTENTIATION OF SYNAPTIC TRANSMISSION COMPRISING COMPOUND HAVING BRAIN SOMATOSTATIN ACTIVATION PROPERTY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-12-07 | — | — | WO | disclosed |
| WO-2000042011-A1 | AMIDE COMPOUNDS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014745-A1 | Amide compounds | CHRM1, CHRM2, CHRNE | EPHX2 328/4885HSD11B1 701/4885PRKAB2 2081/4885 |
| US-20040092528-A1 | Agent for modulating excitatory synaptic transmission comprising a compound having alpha7 nicotinic acetylcholine receptor activation property | CHRNA7, CHRNA5, CHRNA10 | EPHX2 1280/4885HSD11B1 3168/4885PRKAB2 1798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.